Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
7
Bullish
4
Bearish
35
Neutral
7
Bullish
4
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Discovery themes featuring this stock
Beta Drugs develops, manufactures, and markets oncology formulations, including tablets, capsules, injections, lyophilized injections, APIs, contract manufacturing, exports, and branded pharmaceutical products for domestic and international customers.
H1 FY27 revenue grew 29.2%, while PAT increased approximately 45% from INR24 crore to INR34 crore. EBITDA margin remained broadly stable at 23.18%, with management attributing future improvement to business mix, backward integration, operating leverage, and lower financing costs.
The company’s own-branded business grew 17%, despite a temporary plant shutdown that shifted approximately INR6–7 crore of sales into the second half. Management continues targeting roughly INR150 crore branded sales for FY27 and expects 20–22% growth in branded oncology.
Nivian Lifesciences has become a significant growth contributor after acquisition, with H1 revenue rising 75% to INR31 crore. Management sees further potential through IVF-chain expansion, deeper prescriber coverage, new products, and a possible recombinant FSH product within two to three years.
Export growth is supported by 872 registrations in the pipeline, four European dossiers, 35 recent registrations, and approximately 50 more expected during FY27. However, the export model remains tender-driven, meaning commercialization timing can shift between financial years despite strong medium-term potential.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,913 Cr
Low Risk
36.9
37.1
3.0
4.4
2,807.90
990.10
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
470.00 | 2,123 Cr | 85.18 | 10.32 | 0.00 | 5.03 | 4.64 | 1.89 | ||
944.55 | 2,079 Cr | 48.51 | 6.01 | 0.00 | 12.39 | 17.21 | 8.31 | ||
334.55 | 2,001 Cr | -224.30 | 2.46 | 0.00 | -2.93 | -2.42 | -0.71 | ||
214.75 | 1,993 Cr | 62.70 | 1.95 | 0.09 | -7.71 | 1.93 | 1.22 | ||
1720.50 | 1,974 Cr | 37.01 | 4.51 | 0.00 | 11.86 | 16.78 | 8.13 | ||
2265.00 | 1,931 Cr | 14.11 | 5.36 | 0.48 | 15.45 | 14.34 | 20.20 | ||
884.45 | 1,874 Cr | 28.20 | 3.23 | 0.69 | 11.44 | 14.90 | 7.32 | ||
| Median: 7 Co. | — | 884.45 | 1,993 Cr | 37.01 | 4.51 | 0.00 | 11.44 | 14.34 | 7.32 |
Beta Drugs Ltd (BETA) is currently trading at 1,720.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Beta Drugs develops, manufactures, and markets oncology formulations, including tablets, capsules, injections, lyophilized injections, APIs, contract manufacturing, exports, and branded pharmaceutical products for domestic and international customers. H1 FY27 revenue grew 29.2%, while PAT increased approximately 45% from INR24 crore to INR34 crore. EBITDA margin remained broadly stable at 23.18%, with management attributing future improvement to business mix, backward integration, operating leverage, and lower financing costs. The company’s own-branded business grew 17%, despite a temporary plant shutdown that shifted approximately INR6–7 crore of sales into the second half. Management continues targeting roughly INR150 crore branded sales for FY27 and expects 20–22% growth in branded oncology. Nivian Lifesciences has become a significant growth contributor after acquisition, with H1 revenue rising 75% to INR31 crore. Management sees further potential through IVF-chain expansion, deeper prescriber coverage, new products, and a possible recombinant FSH product within two to three years. Export growth is supported by 872 registrations in the pipeline, four European dossiers, 35 recent registrations, and approximately 50 more expected during FY27. However, the export model remains tender-driven, meaning commercialization timing can shift between financial years despite strong medium-term potential.
Over the past 52 weeks, Beta Drugs Ltd has traded between a low of ₹990.10 and a high of ₹2,807.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Beta Drugs Ltd has a market capitalization of approximately 1,913.41. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Beta Drugs Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 36.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,913.41 Cr, Beta Drugs Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Beta Drugs Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Beta Drugs Ltd is 36.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Beta Drugs said Branded Oncology sales were affected by a production shutdown for debottlenecking and capacity expansion at the Adley Formulation Plant. Supply constraints in platinum APIs also hampered sales, and the company said some related orders moved to H2FY27. Branded Oncology still grew 17% in H1FY27.
Beta Drugs reported consolidated non-current borrowings of Rs 27.83 crore at 30 September 2026. This was down from Rs 133.32 crore at 31 March 2026. Current borrowings were Rs 20.86 crore at the September reporting date.
Beta Drugs Limited reported consolidated revenue from operations of ₹263.04 crore in H1 FY27. This was 29.2% higher than ₹203.6 crore reported in H1 FY26.
Beta Drugs reported Q1 FY27 revenue of ₹125.55 crore, up 25.29% year-on-year and 33.62% quarter-on-quarter.
